E
Evi Lianidou
Researcher at National and Kapodistrian University of Athens
Publications - 203
Citations - 8268
Evi Lianidou is an academic researcher from National and Kapodistrian University of Athens. The author has contributed to research in topics: Circulating tumor cell & Cancer. The author has an hindex of 50, co-authored 181 publications receiving 7035 citations. Previous affiliations of Evi Lianidou include Toronto Western Hospital.
Papers
More filters
Journal ArticleDOI
Circulating tumor cells as promising novel biomarkers in solid cancers
TL;DR: Clinical potential of CTCs as novel biomarkers in 10 different types of solid cancers: breast, ovarian, prostate, lung, colorectal, hepatocellular carcinoma, pancreatic, head and neck, bladder cancer and melanoma is focused on.
Journal ArticleDOI
Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR
Areti Strati,Athina Markou,Cleo Parisi,Eleni Politaki,Dimitris Mavroudis,Vasilis Georgoulias,Evi Lianidou +6 more
TL;DR: Molecular characterization of CTCs has revealed a remarkable heterogeneity of gene expression between breast cancer patients and the clinical significance of these findings in early breast cancer remains to be elucidated when the clinical outcome for these patients is known.
Journal ArticleDOI
Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers.
Maria Panagopoulou,Makrina Karaglani,Ioanna Balgkouranidou,Eirini Biziota,Triantafillia Koukaki,Evaggelos Karamitrousis,Evangelia Nena,Ioannis Tsamardinos,George Kolios,Evi Lianidou,Stylianos Kakolyris,Ekaterini Chatzaki +11 more
TL;DR: Blood circulating cell-free DNA emerged as a highly potent predictive classifier in metastatic breast cancer, with great discriminating power to predict response to chemotherapy.
Journal ArticleDOI
Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients.
Andra Kuske,Tobias M. Gorges,Pierre Tennstedt,Anne-Kathrin Tiebel,Raisa S. Pompe,Felix Preißer,Sandra Prues,Martine Mazel,Athina Markou,Evi Lianidou,Sven Peine,Catherine Alix-Panabières,Sabine Riethdorf,Burkhard Beyer,Thorsten Schlomm,Klaus Pantel +15 more
TL;DR: CTC-based liquid biopsies have the potential to monitor MRD in patients with non-metastatic prostate cancer by combining three independent CTC assays: the CellSearch system, an in vivo CellCollector and the EPISPOT.
Journal ArticleDOI
Lung cancer epigenetics: emerging biomarkers
TL;DR: Novel and promising molecular biomarkers for diagnosis and prognosis of lung cancer are continuously emerging in this area, requiring further evaluation, including extensive validation in prospective clinical trials before they can be routinely used in a clinical setting.